Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock ...

French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the ...

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

With the peak flu season often occurring during December and January and even into February, Dr. Sharon Nachman, Chief of the ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

Company planning for every eligible baby in the US to have access to BEYFORTUS <li /> New BEYFORTUS filling line approved by the ...

Barclays analyst Emily Field maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €120.00. The ...

Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for ...